Empowered Funds LLC Takes Position in Lantheus Holdings, Inc. $LNTH

Key Points

• Empowered Funds LLC initiated a position in Lantheus Holdings by purchasing 11,979 shares worth approximately $909,000. Institutional investors collectively own 99.06% of the company.
• Lantheus exceeded quarterly expectations, reporting $1.55 in earnings per share versus the $1.30 consensus estimate and revenue of $388.18 million, up 2.7% year over year.
• Analyst sentiment has softened, with several firms downgrading the stock to “Hold” and reducing price targets. The shares currently have a consensus “Hold” rating and an average target price of $108.11.

Empowered Funds LLC purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm purchased 11,979 shares of the medical equipment provider's stock, valued at approximately $909,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC increased its stake in Lantheus by 190.2% in the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider's stock valued at $87,000 after purchasing an additional 698 shares in the last quarter. First Trust Advisors LP boosted its position in shares of Lantheus by 37.4% during the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider's stock worth $5,714,000 after purchasing an additional 19,008 shares in the last quarter. Baird Financial Group Inc. boosted its position in shares of Lantheus by 22.6% during the second quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider's stock worth $222,000 after purchasing an additional 500 shares in the last quarter. Daiwa Securities Group Inc. grew its holdings in shares of Lantheus by 88.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider's stock valued at $278,000 after buying an additional 1,591 shares during the period. Finally, Osterweis Capital Management Inc. acquired a new position in shares of Lantheus in the 2nd quarter valued at $36,000. Institutional investors own 99.06% of the company's stock.

Lantheus Stock Performance

LNTH opened at $100.95 on Monday. The business's 50-day moving average price is $104.09 and its two-hundred day moving average price is $88.14. Lantheus Holdings, Inc. has a 1 year low of $49.67 and a 1 year high of $111.86. The company has a market capitalization of $6.59 billion, a price-to-earnings ratio of 24.38 and a beta of -0.03. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company had revenue of $388.18 million during the quarter, compared to analysts' expectations of $363.23 million. During the same period in the prior year, the firm earned $1.57 earnings per share. Lantheus's revenue for the quarter was up 2.7% compared to the same quarter last year. Equities analysts expect that Lantheus Holdings, Inc. will post 4.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Brookline Capital Markets downgraded Lantheus from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. CJS Securities cut Lantheus from a "market outperform" rating to a "market perform" rating in a research note on Tuesday, August 4th. Weiss Ratings upgraded Lantheus from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday, July 31st. TD Cowen lowered Lantheus from a "buy" rating to a "hold" rating and dropped their price target for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Finally, Truist Financial cut Lantheus from a "buy" rating to a "hold" rating and cut their price objective for the company from $125.00 to $102.50 in a report on Monday, August 3rd. Five analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $108.11.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source